Sickle cell anemia a type of autosomal recessive disorder which requires treatment to be tolerated well throughout the life, safe and effective too. Preventing complications can be vital in preventing mortality in sickle cell patients. Sickling can be produced by a variety of factors, including hemolysis, cellular hyper-adhesion, oxidative stress, sterile inflammation, endothelial dysfunction, haemostatic activation, and blood hyper viscosity. During a sickling, these factors can cause sickle cell disease patients to become hypercoagulable. As a result, preventing this has become critical in the treatment of sickle cell patients. The formulation has documented anti-sickling activity. The previous studies have already suggested that T-AYU-HM Premium prevents lysis and there by sickling induced complications in sickle cell anemia. Therefore the primary objective of the study is to assess the effectiveness of T-AYU-HM Premium on red blood corpuscles and types of hemoglobin. The sickling induced activation of neutrophils and platelets during hypercoagulation state are might be the reason for causing vasoocclusive pain full crisis in sickle cell patients. Therefore, effectiveness of formulations preventing lysis and sickling can be reflected through the observation of other blood cell parameters in sickle cell anemia patients. Improvement in clinical parameters can be observed physically and through laboratory parameters to confer the effectiveness of formulation in sickle cell anemia patients. Acute pain in patients with sickle cell disease is caused by ischemic tissue injury resulting from the occlusion of microvascular beds by sickle erythrocytes during an acute crisis. Therefore the study emphasizes to evaluate changes in major and minor complains and impact of the treatment on pain and health related quality of life in patients receiving treatment.